PV Bulletin

Psychedelic Drugs: Considerations for Clinical Investigations

The FDA's final guidance document outlines considerations for clinical investigations of psychedelic drugs, focusing on safety and abuse potential.

Primary source: Advisory Committee Guidance Documents

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA published final guidance detailing specific requirements for clinical trials involving psychedelic drugs, effective from July 2026.

Why it matters

As interest in the therapeutic potential of psychedelic drugs grows, adhering to these FDA recommendations is vital for ensuring participant safety and regulatory compliance.

Action needed

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guideline
Policy status
final
Publication date
2026-07-13
Policy change
This final guidance outlines the FDA's considerations for clinical investigations of psychedelic drugs, emphasizing safety monitoring and the assessment of abuse potential.

Key changes

Provides recommendations on clinical trial design, including blinding, the role of psychotherapy, and safety monitoring requirements for drugs with potential psychoactive effects. It addresses the unique safety profile of psychedelics and the need for robust adverse event collection.

Affected workflows

Country Compliance

Responsible groups

Clinical SafetyPharmacovigilance OperationsRegulatory Affairs

PV impact

Clinical safety and PV teams must ensure that safety monitoring protocols for trials involving psychedelics comply with these specific FDA recommendations, particularly regarding the detection and reporting of psychoactive side effects and abuse potential.

View regulator source

Source document details

Exact policy details

Docket Number
FDA-2023-D-1987
Applies to: Applicable to clinical trials for psychedelic drugs.
Docket Number: FDA-2023-D-1987 · p. 1 · High · Source
Guidance Published Date
July 2026
Applies to: The guidance is effective from this date.
Published at: July 2026 · p. 1 · High · Source
Nonclinical Program Requirement
Follow ICH guidance M3(R2)
Applies to: Nonclinical studies for psychedelic drugs should align with ICH guidelines.
The nonclinical program for psychedelic drugs should follow recommendations outlined in the ICH guidance for industry M3(R2). · p. 7 · High · Source
IND Inclusion Requirements
Pharmacological and toxicological studies are required
Applies to: An IND must include adequate safety information before initiating human trials.
An IND must include adequate information about pharmacological and toxicological studies. · p. 7 · High · Source
Abuse Potential Assessment Requirement
Abuse potential evaluation is mandatory
Applies to: All new drug applications must include an assessment of abuse potential.
The assessment of the abuse potential of a drug product under development is generally conducted as a component of its safety evaluation. · p. 10 · High · Source

Workflow rule impacts

Country ComplianceCompliance Department

Increased regulatory scrutiny due to Schedule I status of certain psychedelic compounds.

Need to assess compliance with controlled substances regulations.

Activities associated with investigations under an IND must comply with the Controlled Substances Act. · p. 10 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 13, 2026

Full briefing

Practical implication

Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

The FDA has issued final guidance detailing the necessary considerations for clinical investigations of psychedelic drugs, emphasizing robust safety monitoring protocols and abuse potential assessments. This guidance is crucial for teams engaged in the clinical evaluation of these substances.

What changed: The FDA published final guidance detailing specific requirements for clinical trials involving psychedelic drugs, effective from July 2026.

Why it matters: As interest in the therapeutic potential of psychedelic drugs grows, adhering to these FDA recommendations is vital for ensuring participant safety and regulatory compliance.

Practical implication: Clinical safety and pharmacovigilance teams must implement new safety monitoring protocols and ensure adequate assessment of abuse potential as stipulated in the guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Guideline#final#Reporting Requirement#policy-change#firecrawl-policy-agent#Food and Drug Administration

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward